{
    "clinical_study": {
        "@rank": "153005", 
        "arm_group": {
            "arm_group_label": "Single-arm treatment with Exenatide", 
            "arm_group_type": "Experimental", 
            "description": "Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT"
        }, 
        "brief_summary": {
            "textblock": "The study is designed as an open labeled pilot trial to analyze the acute responses of\n      glucose, GLP-1, GIP, insulin secretory,and glucagon to a mixed meal tolerance test (MMTT) or\n      intravenous glucose tolerance tests (IVGTT) with and without pretreatment with Exenatide\n      (Byetta) 5 mcg sc.\n\n      The investigators will also test the effects of Exenatide on gastric emptying during the\n      MMTT."
        }, 
        "brief_title": "Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  T1D of at least 3 yrs duration.\n\n          -  Male or female aged 18-56 years who meets the American Diabetes Association standard\n             T1DM criteria.\n\n          -  HgbA1c<9%\n\n          -  Insulin requirement of <  0.8 U/kg/d\n\n          -  Absence of severe hypoglycemia in the past 6 months\n\n          -  Absence of ketoacidosis in the past 6 months\n\n          -  Menstruating women must have a negative pregnancy test and be willing to avoid\n             pregnancy during the study period.\n\n          -  Signed informed consent..\n\n        Exclusion Criteria:\n\n          -  Inability or unwillingness to give informed consent.\n\n          -  Prior Exenatide or Liraglutide treatment or use of any medication that could\n             potentially affect diabetes or immunologic status\n\n          -  Known hypersensitivity to Exenatide or any product components\n\n          -  Participation in an investigational treatment trial within the last 6 weeks before\n             enrollment.\n\n          -  Any medical condition that in the opinion of the investigator would interfere with\n             safe completion of the trial such as: epilepsy, atopic disease, active Grave's\n             disease, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular\n             disease, cerebrovascular disease,liver disease, HIV, or any concurrent autoimmune\n             disease except treated and stable thyroid disease\n\n          -  Known severe renal impairment, end-stage renal disease or renal transplantation.\n\n          -  Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis,\n             thyroid nodules or malignancy with the exclusion of a history of localized basal cell\n             carcinoma.\n\n          -  Uncompensated heart failure, fluid overload, myocardial infarction or liver disease\n             within the last 6 weeks before enrollment.\n\n          -  Active clinically serious infections.\n\n          -  Positive pregnancy test in menstruating women or lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "56 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855490", 
            "org_study_id": "1201009520"
        }, 
        "intervention": {
            "arm_group_label": "Single-arm treatment with Exenatide", 
            "intervention_name": "Exenatide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Yale School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta \u00ae) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes", 
        "overall_contact": {
            "email": "tara.ghazi@yale.edu", 
            "last_name": "Tara Ghazi, MD", 
            "phone": "203-737-2737"
        }, 
        "overall_official": {
            "affiliation": "Yale  School of Medicine", 
            "last_name": "Kevan C Herold, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will measure the hormonal and metabolic changes during a mixed meal and intravenous glucose tolerance test with and without exenatide pretreatment in subjects with and without residual insulin production.", 
            "measure": "Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.", 
            "safety_issue": "No", 
            "time_frame": "Each patients is estimated to finish the study within 4-6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855490"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Kevan Herold", 
            "investigator_title": "Professor of Immunobiology and of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "In addition to measuring the levels of glucose and gastric emptying, we will measured glucagon levels, insulin secretion rates, GLP-1 and GIP hormonal levels during the provocative tests.", 
            "measure": "Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D.   - effect of exenatide on residual insulin production", 
            "safety_issue": "Yes", 
            "time_frame": "4-6 weeks"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}